HONG KONG – The CFDA approved the country's first-ever orally administrated and subtype-selective histone deacetylase inhibitor (HDACi). Patients in China with relapsed or refractory peripheral T-cell lymphoma (PTCL) now have an alternative treatment other than traditional chemotherapy.
HONG KONG – The pharmaceutical arm of Chinese conglomerate Fosun Group plans to channel its research and development efforts into biosimilars and generic chemicals with more than ¥5 billion (US$800 million) of investment in the coming years.
HONG KONG – The pharmaceutical arm of Chinese conglomerate Fosun Group plans to channel its research and development efforts into biosimilars and generic chemicals with more than ¥5 billion (US$800 million) of investment in the coming years.
HONG KONG – Chinese pharmaceutical regulators will begin 2015 by taking aim at improving supervision of shelf-life studies and storage of biological products in order to enhance consumer safety.
HONG KONG – Chinese pharmaceutical regulators will begin 2015 by taking aim at improving supervision of shelf-life studies and storage of biological products in order to enhance consumer safety.
HONG KONG – With the advantage of an English-speaking population, precision manufacturing capabilities and courts dedicated to solving intellectual property matters, Malaysia is quickly emerging as a launch pad for biopharmaceutical companies looking to enter the Asian market and regional companies aiming to expand.
HONG KONG – With the advantage of an English-speaking population, precision manufacturing capabilities and courts dedicated to solving intellectual property matters, Malaysia is quickly emerging as a launch pad for biopharmaceutical companies looking to enter the Asian market and regional companies aiming to expand.
